Lynk Pharmaceuticals Announces FDA IND Approval of Its Allosteric TYK2 Inhibitor LNK01006
Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as “Lynk Pharmaceuticals”), a clinical-stage innovative drug development company focused on developing innovative therapies for immune and inflammatory diseases, today announced that its innovative TYK2 allosteric inhibitor, LNK01006, has been approved by U.S. Food and Drug Administration (FDA) for human clinical trials. LNK01006 is a highly brain-penetrant, potent, […]